Company / Operating Income
Vaxcyte, Inc. Operating Income History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$923.7M
FY2025
5-year range
-$923.7M / -$103.7M
FY2021-FY2025
Trend
-62.2%
vs FY2024
Sector context
#198 of 204
Health Care
What the data says
Among 204 Health Care companies, Vaxcyte, Inc. is in the bottom 3% for operating income. Operating Income has declined for 7 consecutive years, from -$36M in FY2018 to -$924M in FY2025.
Based on SEC 10-K filings.
-$924M in FY2025.
Declined from -$468M to -$924M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 204This company -$923.7M Sector average $107.7M
▼
-957.5% below sector average
Key checks
Key Insights
- Vaxcyte, Inc.'s operating income has declined for 7 consecutive years.
- In FY2025, operating income decreased 62.2% year-over-year.
- Ranks #198 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.94 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$923.7M | -62.2% |
| FY2024 | -$569.5M | -21.7% |
| FY2023 | -$468.0M | -101.5% |
| FY2022 | -$232.3M | -124.0% |
| FY2021 | -$103.7M | -15.7% |
| FY2020 | -$89.6M | -65.4% |
| FY2019 | -$54.2M | -52.4% |
| FY2018 | -$35.5M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026